CIA
PBYI icon

Capital Impact Advisors’s Puma Biotechnology PBYI Stock Holding History

Capital Impact Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-147,303
Closed -$1.24M – 122
2020
Q1 		$1.24M Buy
147,303
+8,574
+6% +$83.3K 0.52% 89
2019
Q4 		$1.21M Sell
138,729
-35,912
-21% -$297K 0.43% 108
2019
Q3 		$1.95M Buy
174,641
+47,612
+37% +$514K 0.74% 70
2019
Q2 		$1.61M Buy
127,029
+53,153
+72% +$1.22M 0.59% 102
2019
Q1 		$1.56M Hold
73,876
– – 0.69% 76
2018
Q4 		$1.56M Buy
73,876
+34,667
+88% +$1.04M 0.67% 79
2018
Q3 		$1.8M Buy
39,209
+2,912
+8% +$140K 0.62% 84
2018
Q2 		$2.04M Buy
36,297
+10,068
+38% +$583K 0.76% 47
2018
Q1 		$1.78M Buy
26,229
+11,320
+76% +$848K 0.73% 48
2017
Q4 		$1.47M Hold
14,909
– – 0.64% 69
2017
Q3 		$1.78M Sell
14,909
-3,965
-21% -$369K 0.8% 37
2017
Q2 		$1.65M Sell
18,874
-7,231
-28% -$405K 0.75% 38
2017
Q1 		$971K Buy
+26,105
New +$953K 0.39% 137
2015
Q4 		– Sell
-1,492
Closed -$112K – 273
2015
Q3 		$112K Hold
1,492
– – 0.06% 254
2015
Q2 		$174K Hold
1,492
– – 0.08% 256
2015
Q1 		$352K Buy
+1,492
New +$319K 0.16% 225

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Capital Impact Advisors's PBYI Position: Q2 2020 in Review

Capital Impact Advisors sold out of Puma Biotechnology (PBYI) in Q2 2020, closing a stake of 147,303 shares — an estimated $1.24M sold.

Capital Impact Advisors first reported a position in PBYI in Q1 2015 and held it in 16 quarters. The position peaked at $2.04M in Q2 2018. 128 funds tracked by Wall St. Rank hold PBYI as of Q2 2020.

  • Capital Impact Advisors reported no remaining Puma Biotechnology position as of Q2 2020 after selling out during the quarter.
  • Capital Impact Advisors sold 147,303 Puma Biotechnology shares in Q2 2020, an estimated $1.24M.
  • Capital Impact Advisors first reported a position in Puma Biotechnology in Q1 2015 and held it in 16 quarters.
  • Capital Impact Advisors's Puma Biotechnology position peaked at $2.04M in Q2 2018.
  • 128 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2020.

Based on Capital Impact Advisors's 13F filing for Q2 2020, filed 17 Aug 2020.